No Detail Found!

Serum Versus Vitreous VEGF A and Central Macular Thickness in Diabetic Macular Edema and the effect of Intra-vitreal Bevacizumab on These Variables.

Author(s)
Tayyaba Gul Malik Department of Ophthalmology, LMDC, Lahore, Pakistan
Muhammad Khalil Department of Ophthalmology, LMDC, Lahore, Pakistan
Roquyya Gul CRIMM/ IMBB, The University of Lahore, Pakistan
Syed Shoaib Ahmad CRIMM/ IMBB, The University of Lahore, Pakistan
Sania Munawar Ophthalmology Ghurki Teaching Hospital, Lahore, Pakistan
Abstract
Purpose: To determine a relation among serum VEGF A, vitreous VEGF A and central macular thickness and the effect of intravitreal Bevacizumab on these variables. Study Design: Quasi - experimental study. Place and Duration of Study: Ghurki Trust Teaching Hospital, Lahore. 2014 to 2016. Material and Methods: Fifty patients with clinically significant macular edema diagnosed with 78-D indirect Ophthalmoscopy were recruited. Optical coherence tomography (OCT for macular thickness), serum VEGF A and vitreous VEGF A were analyzed at pre and post (four weeks) intra-vitreal Bevacizumab injection. Measurement of Central sub field thickness, macular cube volume, cube average thickness, vitreous and serum VEGF A levels one month after a single injection of intra-vitreal Bevacizumab were the outcome variables. Results: Out of fifty patients, forty three patients were included with an average age of 56 years. Mean pre-injection VEGF A values were 347.8 ± 92 pg/ml which were reduced to 107.2 ± 16 pg/ml four weeks post intra-vitreal Bevacizumab ( p = 0.000). Mean pre-injection VEGF A level in vitreous was 701.9 ± 145 pg/ml and post injection 82.66 ± 21 pg/ml (p = 0.000). Pre and post injection central sub field thickness (CST) was 410 ± 24 µm and 299.6 ±15 µm respectively with p values of 0.000. Mean pre injection cube volume (CV) and cube average thickness (CAT) were 12 ± 0.36 mm3 and 355.7 ± 10 µm which were reduced to 11± 0.26 mm3 and 304 ± 9 µm after injection. Conclusion: From this study, a direct relation of vitreous VEGF A, serum VEGF A and central sub field thickness is confirmed. Statistically significant absorption of intra-vitreal Bevacizumab occurs into the systemic circulation and effect of intra vitreal Bevacizumab on the fellow eyes is an additional benefit
Publication Details
Page(s) 78-83
DOI DOI not available
Published Journal: Pakistan Journal of Ophthalmology , Volume: 32, Issue: 2, Year: 2016

Request the full text from PASTIC

Keywords
Cube average volume, Bevacizumzb, VEGF A
0

Citations

0

Downloads

25

Views